Viewing Study NCT02516969

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:54 PM
Ignite Modification Date: 2026-02-25 @ 8:17 PM
Study NCT ID: NCT02516969
Status: COMPLETED
Last Update Posted: 2022-01-14
First Post: 2015-07-30
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Sponsor:
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006258', 'term': 'Head and Neck Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D016634', 'term': 'Radiosurgery'}], 'ancestors': [{'id': 'D011878', 'term': 'Radiotherapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D013238', 'term': 'Stereotaxic Techniques'}, {'id': 'D019635', 'term': 'Neurosurgical Procedures'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'stadtermanbm@upmc.edu', 'phone': '412-647-5554', 'title': 'Barbara M. Stadterman, MPH, MSCR, CCRP', 'organization': 'UPMC Hillman Cancer Center'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Up to 24 months', 'description': 'Adverse events are Grade 1 and 2 and Serious Adverse events are Grade 3 and 4 events per National Cancer Institute Common Toxicity Criteria Events Scale (CTCAE), v4.', 'eventGroups': [{'id': 'EG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 3, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy treatment', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 2, 'seriousNumAtRisk': 4, 'deathsNumAffected': 2, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Dysphagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Dysphonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Edema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Lymphedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Odynophagia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Radiation Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Xerostomia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Dysgeusia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Fibrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Otalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'telangiectasia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Trismus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Aspiration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Infection (Thrush)', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}], 'seriousEvents': [{'term': 'Oral Mucositis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 4, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'CTCAE (4.0)'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': '1-year Local Control', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy treatment'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median survival is not reached. Insufficient number of participants with event of (local) progression.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Upper bound of 95% CI not available. Insufficient number of participants with event of (local) progression.', 'groupId': 'OG001', 'lowerLimit': '2', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to 1 year', 'description': 'Local progression-free-survival (LPFS) is the number of months from the initiation of study treatment until (local) progression of disease or death from any cause. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Acute Toxicities of Adjuvant SBRT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy'}], 'classes': [{'title': 'Grade 3 - Oral Mucositis', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Dysphagia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Dysphonia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Edema', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Fatigue', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Lymphedema', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Odynophagia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Pain', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Radiation Dermatitis', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Xerostomia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Xerostomia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Pain', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Dysgeusia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Fibrosis', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Jaw Pain', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Otalgia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 telangiectasia', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Trismus', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 2 years', 'description': 'Toxicities are assess according to the National Cancer Institute Common Toxicity Criteria Events Scale (CTCAE), v4. Acute toxicities are those seen within 3 months of completion of Stereotactic Body Radiotherapy. Toxicity in patients is documented immediately prior to randomization and 8-12 weeks post-treatment. Adverse events are Grade 1 and 2 and Serious Adverse events are Grade 3 and 4 events.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Late Toxicities of Adjuvant SBRT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy treatment'}], 'classes': [{'title': 'Grade 3 Pneumonia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Aspiration', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Dysgeusia', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Dysphagia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Fatigue', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Fibrosis', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Fibrosis', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Infection (Thrush)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Lymphedema', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Lymphedema', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Pain', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Trismus', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Ulceration', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 1 Xerostomia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Grade 2 Xerostomia', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to 2 years', 'description': 'Toxicities will be assessed according to the National Cancer Institute Common Toxicity Criteria Events Scale (CTCAE), v4. Late toxicities will be those seen after 3 months of completion of Stereotactic Body Radiotherapy. Adverse events are Grade 1 and 2 and Serious Adverse events are Grade 3 and 4 events.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}, {'type': 'SECONDARY', 'title': 'Progression-free Survival (PFS) Locoregional', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy treatment'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median LRPFS not reached. The 95% CI not available. Insufficient number of participants with event of (locoregional) progression.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median LRPFS not reached. Upper bound of 95% CI not available. Insufficient number of participants with event of (locoregional) progression.', 'groupId': 'OG001', 'lowerLimit': '2', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to 2 years', 'description': 'LRPFS is defined as the time from the date of randomization to the date of local or regional recurrence, whichever occurs first, or the date of death from any cause. Subjects who are alive and have not progressed will be censored at their last follow-up date. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}, {'type': 'SECONDARY', 'title': 'Progression-free Survival (DPFS) Distant', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy treatment'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median DPFS not reached. The 95% CI not available. Insufficient number of participants with event of (distant) progression.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median DPFS not reached. Upper bound of 95% CI not available. Insufficient number of participants with event of (distant) progression.', 'groupId': 'OG001', 'lowerLimit': '11', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to 2 years', 'description': 'Distant progression-free-survival (DPFS) is the time from the date of randomization to the date of distant progression or the date of death from any cause. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}, {'type': 'SECONDARY', 'title': 'Overall Progression Free Survival (PFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy treatment'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median survival not reached. The 95% CI not available. Insufficient number of participants with event of progression.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median survival not reached. Upper bound of 95% CI not available. Insufficient number of participants with event of progression.', 'groupId': 'OG001', 'lowerLimit': '2', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to 2 years', 'description': 'Overall progression free survival is the total of the three survival time measurements; PFS = local + regional + distant. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}, {'type': 'SECONDARY', 'title': 'Overall Survival (OS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation', 'description': 'No Stereotactic Body Radiotherapy treatment'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Median OS not reached. 95% CI was not available. Insufficient number of participants with event of death.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Median OS not reached. 95% CI was not available. Insufficient number of participants with event of death.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to 5 years', 'description': 'The overall survival time is the measurement of time between the date of randomization and death from any cause.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}, {'type': 'SECONDARY', 'title': 'Quality of Life (UW-QoL-R)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'OG001', 'title': 'Observation', 'description': 'No Stereotactic Body Radiotherapy treatment'}], 'classes': [{'title': 'Period 1: Pain', 'categories': [{'measurements': [{'value': '100.00', 'groupId': 'OG000', 'lowerLimit': '100.00', 'upperLimit': '100.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '75.00', 'upperLimit': '75.00'}]}]}, {'title': 'Period 2: Pain', 'categories': [{'measurements': [{'value': '100.00', 'groupId': 'OG000', 'lowerLimit': '100.00', 'upperLimit': '100.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '37.50', 'upperLimit': '100.00'}]}]}, {'title': 'Period 3: Pain', 'categories': [{'measurements': [{'value': '75.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '75.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Appearance', 'categories': [{'measurements': [{'value': '75.00', 'groupId': 'OG000', 'lowerLimit': '75.00', 'upperLimit': '75.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '75.00', 'upperLimit': '75.00'}]}]}, {'title': 'Period 2: Appearance', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '50.00'}, {'value': '87.50', 'groupId': 'OG001', 'lowerLimit': '50.00', 'upperLimit': '100.00'}]}]}, {'title': 'Period 3: Appearance', 'categories': [{'measurements': [{'value': '75.00', 'groupId': 'OG000', 'lowerLimit': '62.50', 'upperLimit': '100.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Activity', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '50.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '75.00', 'upperLimit': '75.00'}]}]}, {'title': 'Period 2: Activity', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '50.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '62.50', 'upperLimit': '87.50'}]}]}, {'title': 'Period 3: Activity', 'categories': [{'measurements': [{'value': '62.50', 'groupId': 'OG000', 'lowerLimit': '62.50', 'upperLimit': '75.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Recreation', 'categories': [{'measurements': [{'value': '62.50', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '75.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '75.00', 'upperLimit': '75.00'}]}]}, {'title': 'Period 2: Recreation', 'categories': [{'measurements': [{'value': '25.00', 'groupId': 'OG000', 'lowerLimit': '25.00', 'upperLimit': '25.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '62.50', 'upperLimit': '87.50'}]}]}, {'title': 'Period 3: Recreation', 'categories': [{'measurements': [{'value': '62.50', 'groupId': 'OG000', 'lowerLimit': '62.50', 'upperLimit': '75.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Swallowing', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '67.00', 'upperLimit': '67.00'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '67.00', 'upperLimit': '67.00'}]}]}, {'title': 'Period 2: Swallowing', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '67.00', 'upperLimit': '67.00'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '33.50', 'upperLimit': '83.50'}]}]}, {'title': 'Period 3: Swallowing', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '67.00', 'upperLimit': '67.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Chewing', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '100.00'}, {'value': '100.00', 'groupId': 'OG001', 'lowerLimit': '100.00', 'upperLimit': '100.00'}]}]}, {'title': 'Period 2: Chewing', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '50.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '50.00', 'upperLimit': '100.00'}]}]}, {'title': 'Period 3: Chewing', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '100.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Speech', 'categories': [{'measurements': [{'value': '75.25', 'groupId': 'OG000', 'lowerLimit': '67.00', 'upperLimit': '83.50'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '67.00', 'upperLimit': '67.00'}]}]}, {'title': 'Period 2: Speech', 'categories': [{'measurements': [{'value': '33.00', 'groupId': 'OG000', 'lowerLimit': '33.00', 'upperLimit': '33.00'}, {'value': '100.00', 'groupId': 'OG001', 'lowerLimit': '100.00', 'upperLimit': '100.00'}]}]}, {'title': 'Period 3: Speech', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '66.50', 'upperLimit': '100.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Shoulder', 'categories': [{'measurements': [{'value': '100.00', 'groupId': 'OG000', 'lowerLimit': '100.00', 'upperLimit': '100.00'}, {'value': '100.00', 'groupId': 'OG001', 'lowerLimit': '100.00', 'upperLimit': '100.00'}]}]}, {'title': 'Period 2: Shoulder', 'categories': [{'measurements': [{'value': '100.00', 'groupId': 'OG000', 'lowerLimit': '100.00', 'upperLimit': '100.00'}, {'value': '100.00', 'groupId': 'OG001', 'lowerLimit': '83.50', 'upperLimit': '100.00'}]}]}, {'title': 'Period 3: Shoulder', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '66.50', 'upperLimit': '100.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Taste', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '33.00', 'upperLimit': '67.00'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '67.00', 'upperLimit': '67.00'}]}]}, {'title': 'Period 2: Taste', 'categories': [{'measurements': [{'value': '33.00', 'groupId': 'OG000', 'lowerLimit': '33.00', 'upperLimit': '33.00'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '50.00', 'upperLimit': '83.50'}]}]}, {'title': 'Period 3: Taste', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '67.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Saliva', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '33.00', 'upperLimit': '67.00'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '67.00', 'upperLimit': '67.00'}]}]}, {'title': 'Period 2: Saliva', 'categories': [{'measurements': [{'value': '0.00', 'groupId': 'OG000', 'lowerLimit': '0.00', 'upperLimit': '0.00'}, {'value': '83.50', 'groupId': 'OG001', 'lowerLimit': '50.00', 'upperLimit': '100.00'}]}]}, {'title': 'Period 3: Saliva', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '33.00', 'upperLimit': '76.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Mood', 'categories': [{'measurements': [{'value': '75.00', 'groupId': 'OG000', 'lowerLimit': '75.00', 'upperLimit': '75.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '75.00', 'upperLimit': '75.00'}]}]}, {'title': 'Period 2: Mood', 'categories': [{'measurements': [{'value': '50.00', 'groupId': 'OG000', 'lowerLimit': '50.00', 'upperLimit': '50.00'}, {'value': '75.00', 'groupId': 'OG001', 'lowerLimit': '50.00', 'upperLimit': '75.00'}]}]}, {'title': 'Period 3: Mood', 'categories': [{'measurements': [{'value': '75.00', 'groupId': 'OG000', 'lowerLimit': '75.00', 'upperLimit': '75.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Period 1: Anxiety', 'categories': [{'measurements': [{'value': '83.50', 'groupId': 'OG000', 'lowerLimit': '67.00', 'upperLimit': '100.00'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '67.00', 'upperLimit': '67.00'}]}]}, {'title': 'Period 2: Anxiety', 'categories': [{'measurements': [{'value': '67.00', 'groupId': 'OG000', 'lowerLimit': '67.00', 'upperLimit': '67.00'}, {'value': '67.00', 'groupId': 'OG001', 'lowerLimit': '50.00', 'upperLimit': '83.50'}]}]}, {'title': 'Period 3: Anxiety', 'categories': [{'measurements': [{'value': '100.00', 'groupId': 'OG000', 'lowerLimit': '67.00', 'upperLimit': '100.00'}, {'value': 'NA', 'comment': 'Survey not completed by patient(s).', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to 2 years', 'description': 'The University of Washington Quality of Life questionnaire (revised) is a self-administered 16 item inquiry given to patients with head and neck cancer. The first 12 items ask the patient to score domains (such as pain, appearance, swallowing) from 0 (worse) to 100 (best). The arithmetic mean is then computed, yielding one number between 0 and 100. The higher the number, the "better" the patient is considered to be faring. The item simply asks the patient to choose the top 3 issues which have been bothering the patient over the past 7 days. The issues include physical symptoms, emotions and appearance. The final 3 questions provide a global assessment by asking the patient to consider their overall well-being over the past 7 days and provide possible answers ranging from excellent to very poor. For trial analysis: Period=1: before surgery, Period=2: after surgery, but before SBRT for patients in the SBRT arm, Period=3: after SBRT.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Inter-Quartile Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients with/without SBRT treatment.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'FG001', 'title': 'Observation', 'description': 'No Stereotactic Body Radiotherapy'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Stereotactic Body Radiotherapy', 'description': 'Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.'}, {'id': 'BG001', 'title': 'Observation Cohort', 'description': 'No Stereotactic Body Radiotherapy'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '63', 'groupId': 'BG000', 'lowerLimit': '58.00', 'upperLimit': '67.00'}, {'value': '64', 'groupId': 'BG001', 'lowerLimit': '58.00', 'upperLimit': '71.50'}, {'value': '63', 'groupId': 'BG002', 'lowerLimit': '58', 'upperLimit': '67'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'INTER_QUARTILE_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Karnofsky Performance Status (KPS)', 'classes': [{'categories': [{'measurements': [{'value': '80.0', 'groupId': 'BG000', 'lowerLimit': '60.00', 'upperLimit': '80.00'}, {'value': '80.0', 'groupId': 'BG001', 'lowerLimit': '80.00', 'upperLimit': '85.00'}, {'value': '80.0', 'groupId': 'BG002', 'lowerLimit': '80.0', 'upperLimit': '80.0'}]}]}], 'paramType': 'MEDIAN', 'description': "The Karnofsky Performance Status (KPS) scores range 0 - 100. Higher KPS scores means the patient is better able to carry out daily activities, used to determine a patient's prognosis, and used to measure changes in a patient's overall ability to function.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'INTER_QUARTILE_RANGE'}], 'populationDescription': 'All patients participating in the trial.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-04-29', 'size': 499457, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2021-10-26T16:36', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 7}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-12', 'completionDateStruct': {'date': '2021-08-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-12-16', 'studyFirstSubmitDate': '2015-07-30', 'resultsFirstSubmitDate': '2021-10-27', 'studyFirstSubmitQcDate': '2015-08-05', 'lastUpdatePostDateStruct': {'date': '2022-01-14', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-12-16', 'studyFirstPostDateStruct': {'date': '2015-08-06', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2022-01-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-05-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': '1-year Local Control', 'timeFrame': 'Up to 1 year', 'description': 'Local progression-free-survival (LPFS) is the number of months from the initiation of study treatment until (local) progression of disease or death from any cause. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With Acute Toxicities of Adjuvant SBRT', 'timeFrame': 'Up to 2 years', 'description': 'Toxicities are assess according to the National Cancer Institute Common Toxicity Criteria Events Scale (CTCAE), v4. Acute toxicities are those seen within 3 months of completion of Stereotactic Body Radiotherapy. Toxicity in patients is documented immediately prior to randomization and 8-12 weeks post-treatment. Adverse events are Grade 1 and 2 and Serious Adverse events are Grade 3 and 4 events.'}, {'measure': 'Number of Participants With Late Toxicities of Adjuvant SBRT', 'timeFrame': 'Up to 2 years', 'description': 'Toxicities will be assessed according to the National Cancer Institute Common Toxicity Criteria Events Scale (CTCAE), v4. Late toxicities will be those seen after 3 months of completion of Stereotactic Body Radiotherapy. Adverse events are Grade 1 and 2 and Serious Adverse events are Grade 3 and 4 events.'}, {'measure': 'Progression-free Survival (PFS) Locoregional', 'timeFrame': 'Up to 2 years', 'description': 'LRPFS is defined as the time from the date of randomization to the date of local or regional recurrence, whichever occurs first, or the date of death from any cause. Subjects who are alive and have not progressed will be censored at their last follow-up date. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.'}, {'measure': 'Progression-free Survival (DPFS) Distant', 'timeFrame': 'Up to 2 years', 'description': 'Distant progression-free-survival (DPFS) is the time from the date of randomization to the date of distant progression or the date of death from any cause. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.'}, {'measure': 'Overall Progression Free Survival (PFS)', 'timeFrame': 'Up to 2 years', 'description': 'Overall progression free survival is the total of the three survival time measurements; PFS = local + regional + distant. Progression is defined as the appearance of a new metastatic lesion or objective tumor progression. Clinically detected lesions will only be considered measurable when superficial (vis-à-vis skin modules and palpable lymph nodes). The lesion must be accurately measured in at least one dimension ≥ 10mm. Methods for measuring disease status include CT, PET/CT or MRI.'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Up to 5 years', 'description': 'The overall survival time is the measurement of time between the date of randomization and death from any cause.'}, {'measure': 'Quality of Life (UW-QoL-R)', 'timeFrame': 'Up to 2 years', 'description': 'The University of Washington Quality of Life questionnaire (revised) is a self-administered 16 item inquiry given to patients with head and neck cancer. The first 12 items ask the patient to score domains (such as pain, appearance, swallowing) from 0 (worse) to 100 (best). The arithmetic mean is then computed, yielding one number between 0 and 100. The higher the number, the "better" the patient is considered to be faring. The item simply asks the patient to choose the top 3 issues which have been bothering the patient over the past 7 days. The issues include physical symptoms, emotions and appearance. The final 3 questions provide a global assessment by asking the patient to consider their overall well-being over the past 7 days and provide possible answers ranging from excellent to very poor. For trial analysis: Period=1: before surgery, Period=2: after surgery, but before SBRT for patients in the SBRT arm, Period=3: after SBRT.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['Stereotactic Body Radiotherapy (SBRT)'], 'conditions': ['Head and Neck Cancer']}, 'descriptionModule': {'briefSummary': 'Comparison of patients with operable, recurrent previously-irradiated squamous cell head-and-neck cancers with or without adjuvant SBRT.', 'detailedDescription': 'This study aims to determine prognostic factors that may predict the likelihood of local failure, regional failure, to guide future management, to compare the impact of adjuvant SBRT versus a wait-and-see approach on patient reported quality of life (PR-QoL), and to compare surgical versus SBRT-induced immunological serum markers in relation to local control. Recruitment includes patients with recurrent or second-primary head-and-neck squamous cell carcinomas within a previously-irradiated field with high-risk features compromised/positive surgical margins or extra-nodal extension) following macroscopic complete (R0/R1) salvage surgery.\n\nParticipants receive Stereotactic Body Radiotherapy at the following levels:\n\nTreatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols. Evaluations to compare the efficacy of adjuvant SBRT versus wait-and-see, include Local Control, Regional and distant control, Progression-free survival, Overall survival and Patient-Reported Quality-of-Life (PR-QoL).\n\nEvaluations conducted to assess the safety of adjuvant SBRT following salvage surgery include recording of all toxicity data per National Cancer Institute Common Toxicity Criteria Events Scale version 4.0 and prospectively administering the previously-validated University of Washington Quality-of-Life-Revised (UW-QoL-R) questionnaire measuring patient-reported quality-of-life (PR-QoL).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Pathologically proven recurrent or second-primary head-and-neck cancer receiving prior radiotherapy with or without chemotherapy.\n* Prior radiotherapy to a dose of ≥50Gy\n* No evidence of distant metastases\n* Macroscopic complete salvage surgery with curative intent (surgery was not performed only for biopsy or palliation). Final pathology and imaging must indicate a R0 or R1 resection (no gross disease remaining).\n* High-risk pathologic features must be present: compromised/positive surgical margins (≤ 2mm) or extra-nodal extension (patient with other high-risk features gross perinueral invasion, bone invasion, angiolyphatic invasion, or a constellation of these factors may be eligible based on case-by-case basis at discretion of principal investigator).\n* Karnofsky Performance Status ≥60 (ECOG 0-2)\n* Any number or type of prior chemotherapy is allowed (patient may receive concurrent or adjuvant systemic therapy such as cetuximab at the discretion of the treating oncologic team)\n\nExclusion Criteria:\n\n* Evidence of distant metastases on any staging or imaging modality\n* Women who are breast feeding, or have a positive pregnancy test (reproductive age should use effective birth control during study if randomized to SBRT treatment arm)\n* Any patient with gross residual disease following salvage surgery\n* Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the principal investigator.'}, 'identificationModule': {'nctId': 'NCT02516969', 'briefTitle': 'Surgery With or Without Adjuvant Stereotactic Body Radiotherapy', 'organization': {'class': 'OTHER', 'fullName': 'University of Pittsburgh'}, 'officialTitle': 'A Prospective, Randomized Phase II Study of Surgery With or Without Adjuvant Stereotactic Body Radiotherapy (SBRT) in Patients With Previously-Irradiated Head and Neck Cancer', 'orgStudyIdInfo': {'id': '14-151'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Stereotactic Body Radiotherapy', 'description': 'Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes \\<25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.', 'interventionNames': ['Radiation: Stereotactic Body Radiotherapy']}], 'interventions': [{'name': 'Stereotactic Body Radiotherapy', 'type': 'RADIATION', 'otherNames': ['SBRT'], 'description': 'Radiation', 'armGroupLabels': ['Stereotactic Body Radiotherapy']}]}, 'contactsLocationsModule': {'locations': [{'zip': '15232', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'UPMC Shadyside Radiation Oncology', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}], 'overallOfficials': [{'name': 'David A Clump, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Pittsburgh'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'David A. Clump, MD, PhD', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Associate Professor', 'investigatorFullName': 'David A. Clump, MD, PhD', 'investigatorAffiliation': 'University of Pittsburgh'}}}}